CN111372605B - 用于产生流感ha裂解疫苗的方法 - Google Patents

用于产生流感ha裂解疫苗的方法 Download PDF

Info

Publication number
CN111372605B
CN111372605B CN201880070955.0A CN201880070955A CN111372605B CN 111372605 B CN111372605 B CN 111372605B CN 201880070955 A CN201880070955 A CN 201880070955A CN 111372605 B CN111372605 B CN 111372605B
Authority
CN
China
Prior art keywords
influenza
vaccine
split vaccine
split
membrane fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880070955.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111372605A (zh
Inventor
高桥宜圣
安达悠
阿户学
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Infectious Diseases
Original Assignee
National Institute of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Infectious Diseases filed Critical National Institute of Infectious Diseases
Priority claimed from PCT/JP2018/032537 external-priority patent/WO2019045090A1/ja
Publication of CN111372605A publication Critical patent/CN111372605A/zh
Application granted granted Critical
Publication of CN111372605B publication Critical patent/CN111372605B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880070955.0A 2017-09-04 2018-09-03 用于产生流感ha裂解疫苗的方法 Active CN111372605B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2017-169230 2017-09-04
JP2017169230 2017-09-04
JP2018137952A JP7403733B2 (ja) 2017-09-04 2018-07-23 インフルエンザｈａスプリットワクチンの製造方法
JP2018-137952 2018-07-23
PCT/JP2018/032537 WO2019045090A1 (ja) 2017-09-04 2018-09-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (2)

Publication Number Publication Date
CN111372605A CN111372605A (zh) 2020-07-03
CN111372605B true CN111372605B (zh) 2024-12-17

Family

ID=65815411

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880070955.0A Active CN111372605B (zh) 2017-09-04 2018-09-03 用于产生流感ha裂解疫苗的方法

Country Status (10)

Country Link
US (1) US11732031B2 (enExample)
EP (1) EP3679948A4 (enExample)
JP (1) JP7403733B2 (enExample)
KR (1) KR102733152B1 (enExample)
CN (1) CN111372605B (enExample)
AU (1) AU2018325899B2 (enExample)
CA (1) CA3074581A1 (enExample)
EA (1) EA202090587A1 (enExample)
PH (1) PH12020500414A1 (enExample)
SG (1) SG11202001937TA (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
US12059462B2 (en) 2018-07-23 2024-08-13 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
CA3132578A1 (en) 2019-03-04 2020-09-10 Japan As Represented By Director General Of National Institute Of Infectious Diseases Method for producing influenza ha split vaccine
EP4054630A2 (en) * 2019-11-07 2022-09-14 Seqirus UK Limited Compositions and methods for producing a viral vaccine with reduced particle size

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302317A (zh) * 2012-05-16 2015-01-21 Kj生物科学有限公司 新型和改进的流感疫苗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
US8044056B2 (en) 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
BRPI0911699B8 (pt) 2008-07-25 2023-02-28 Inst Res Biomedicine vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste
WO2010047509A2 (ko) 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
CN101524538A (zh) * 2009-03-26 2009-09-09 成都康华生物制品有限公司 一种流感-大流行流感二价联合疫苗及其制备方法
MX338758B (es) 2010-03-08 2016-04-29 Celltrion Inc Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a.
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
KR101960928B1 (ko) 2011-04-21 2019-07-17 올로지 바이오서비시즈, 인크. 백신으로부터 항원을 단리하고 정량하기 위한 방법
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
CN106794241A (zh) * 2014-08-18 2017-05-31 圣诺菲·帕斯图尔公司 烷基化流感疫苗
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
US12059462B2 (en) 2018-07-23 2024-08-13 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302317A (zh) * 2012-05-16 2015-01-21 Kj生物科学有限公司 新型和改进的流感疫苗

Also Published As

Publication number Publication date
KR20200047629A (ko) 2020-05-07
EP3679948A4 (en) 2021-04-28
EP3679948A1 (en) 2020-07-15
AU2018325899B2 (en) 2023-04-20
SG11202001937TA (en) 2020-04-29
KR102733152B1 (ko) 2024-11-21
JP7403733B2 (ja) 2023-12-25
PH12020500414A1 (en) 2021-03-08
US11732031B2 (en) 2023-08-22
JP2019043937A (ja) 2019-03-22
CA3074581A1 (en) 2019-03-07
EA202090587A1 (ru) 2020-08-24
US20190345231A1 (en) 2019-11-14
CN111372605A (zh) 2020-07-03
AU2018325899A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
US12268737B2 (en) Stabilized influenza hemagglutinin stem region trimers and uses thereof
CN111372605B (zh) 用于产生流感ha裂解疫苗的方法
US20230346911A1 (en) Broadly protective influenza b virus vaccines
IL303650B1 (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
Du et al. Flu universal vaccines: new tricks on an old virus
US12491240B2 (en) Method for producing influenza HA split vaccine
JP2023052092A (ja) 免疫原性組成物
CA2826234A1 (en) Novel vaccines against the a/h1n1 pandemic flu virus
US8883165B2 (en) Modified peptide vaccine derived from influenza M2
US20230406910A1 (en) Method for producing influenza ha split vaccine
TWI857017B (zh) 流感ha裂解疫苗之製造方法
HK40032891A (en) Method for producing influenza ha split vaccine
EA045852B1 (ru) Способ получения сплит-вакцины с ha гриппа
EA045912B1 (ru) Способ приготовления сплит-вакцины на основе гемагглютинина гриппа
Mardanova et al. High immunogenicity of plant-produced influenza based on the M2e peptide fused to flagellin
HK40068192A (en) Method for preparing influenza ha split vaccine
HK1139066B (en) Precipitated/inactivated influenza vaccine and method for production thereof
HK1139066A (en) Precipitated/inactivated influenza vaccine and method for production thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210113

Address after: Tokyo, Japan

Applicant after: Representative of the director of the National Institute of infectious diseases of Japan

Address before: Tokyo, Japan

Applicant before: JAPAN HEALTH SCIENCES FOUNDATION

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant